Instem, a global leader in SaaS solutions for life sciences R&D, today announced a 5-year extension of its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA).
Unifying Science and Safety to Navigate the Iterative Path of Lead Optimization
Discover how Instem’s Advance™, Predict™, and BioRails® accelerate early-stage drug discovery by unifying in silico insights, experimental data, and streamlined workflows.
With integrated, insight‑driven platforms that cut through data complexity and eliminate fragmented workflows, Instem empowers researchers to reduce risk, boost efficiency, and accelerate the journey from discovery to IND submission.
NAMs have the potential to deliver more efficient safety assessments, enabling faster and more confident development decisions while also supporting more ethical drug development.
Every breakthrough begins with a single molecule. Follow the journey from early research to regulatory submission and learn how Instem helps teams work more efficiently, reduce risk, and deliver safer, more effective therapies to patients...
